68176-57-8

Usage

Uses

Used in Polymer Industry:
4-(TERT-BUTYL)-1,2-DIAMINOBENZENE is used as a co-catalyst for the polymerization of o-phenylenediamine and its derivatives. Its role in the polymerization process is to enhance the reaction rate and improve the overall efficiency of the process. 4-(TERT-BUTYL)-1,2-DIAMINOBENZENE's ability to act as a co-catalyst is attributed to its amine groups, which can form temporary bonds with the growing polymer chains, facilitating the addition of more monomer units.

InChI:InChI=1/C10H16N2/c1-10(2,3)7-4-5-8(11)9(12)6-7/h4-6H,11-12H2,1-3H3

Upstream product

• 6310-19-6 4-tert-butyl-2-nitroaniline 
• 253185-03-4 tert-butylbenzene 
• 3282-56-2 4-tert-butylnitrobenzene 
• 5369-19-7 3-tert-butylaniline 
• 6933-55-7 acetic acid-(5-tert-butyl-2-nitro-anilide) 
• 38382-35-3 N-[3-(tert-butyl)phenyl]acetamide 
• 40655-37-6 N-(4-(tert-butyl)-2-nitrophenyl)acetamide 
• 20330-45-4 4-tert-butylacetanilide 
• 769-92-6 4-tert-Butylaniline 

Downstream Products

• 342045-53-8 6-tert-butyl-2,3-diphenylquinoxaline 
• 99840-59-2 5-(1,1-dimethylethyl)-1,3-dihydrobenzimidazol-2-one 
• 1046113-83-0 6-tert-butyl-2-{(E)-2-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-vinyl}-1H-benzimidazole trifluoroacetate 
• 1197337-06-6 C₂₀H₂₀N₄O 
• 1221962-07-7 4-(5-tert-butyl-2-benzimidazolyl)-3-(4-chlorophenyl)butanoic acid monohydrochloride 
• 1380291-85-9 3-{[(2-amino-4-tert-butylphenyl)carbamoyl]methyl}-N-methoxy-N-methylcyclobutane-1-carboxamide 
• 1381763-08-1 N₁-(2-amino-4-(tert-butyl)phenyl)-N₅-(((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)-N₅-isopropylglutaramide 
• 1425795-64-7 5-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 1449473-59-9 2-(5-tert-butyl-1H-benzimidazol-2-yl)piperidin-3-ol 
• 1449473-97-5 (2R,3S)-3-amino-3-(5-tert-butyl-1H-benzimidazol-2-yl)-2-methylpropanamide 

Relevant academic research and scientific papers

Spectroscopic and computational investigations of the thermodynamics of boronate ester and diazaborole self-assembly

The solution phase self-assembly of boronate esters, diazaboroles, oxathiaboroles, and dithiaboroles from the condensation of arylboronic acids with aromatic diol, diamine, hydroxythiol, and dithiol compounds in chloroform has been investigated by 1H NMR spectroscopy and computational methods. Six arylboronic acids were included in the investigations with each boronic acid varying in the substituent at its 4-position. Both computational and experimental results show that the para-substituent of the arylboronic acid does not significantly influence the favorability of forming a condensation product with a given organic donor. The type of donor, however, greatly influences the favorability of self-assembly. 1H NMR spectroscopy indicates that condensation reactions between arylboronic acids and catechol to give boronate esters are the most favored thermodynamically, followed by diazaborole formation. Computational investigations support this conclusion. Neither oxathiaboroles nor dithiaboroles form spontaneously at equilibrium in chloroform at room temperature. Computational results suggest that the effect of borylation on the frontier orbitals of each donor helps to explain differences in the favorability of their condensation reactions with arylboronic acids. The results can inform the use of boronic acids as they are increasingly utilized in the dynamic self-assembly of organic materials and as components in dynamic combinatorial libraries.

Structure-activity relationship of omeprazole and analogues as Helicobacter pylori urease inhibitors

Helicobacter pylori urease belongs to a family of highly conserved urea- hydrolyzing enzymes. A common feature of these enzymes is the presence of two Lewis acid nickel ions and a reactive cysteine residue in the active site. The H+/K+-ATPase inhibitor omeprazole is a prodrug of a sulfenamide which covalently modifies cysteine residues on the luminal side of the H+/K+- ATPase of gastric parietal cells. Omeprazole and eight analogues were selected based on their chemical, electronic, and kinetic properties, and each was incubated with viable H. pylori in phosphate-buffered saline at pH 7.4 for 30 min, after which 100 mM urea was added and the amount of ammonia formed analyzed after a further 10 min. Inhibition between 0% and 100% at a 0.1 mM concentration was observed for the different analogues and could be expressed as a function of the pK(a)-value of the pyridine, the pK(a)-value of the benzimidazole, the overall lipophilicity, and, most importantly, the rate of sulfenamide formation, in a quantitative structure-activity relationship. The inhibition was potentiated by a lower pH (favoring the formation of the sulfenamide) but abolished in the presence of β- mercaptoethanol (a scavenger of the sulfenamide). Structural analogues incapable of yielding the sulfenamide did not inhibit ammonia production. Treatment of Helicobacter felis-infected mice with 230 μmol/kg flurofamide b.i.d. for 4 weeks, known to potently inhibit urease activity in vivo, as a means of eradicating the infection, was tested and compared with the effect of 125 μmol/kg omeprazole b.i.d. for 4 weeks. Neither treatment proved efficacious.

Process for the manufacture of benzimidazolones-(2)

Process for the manufacture of benzimidazolones-(2) wherein an o-phenylenediamine is reacted with optionally alkylated urea in the ratio of 1 to 1.3 moles per mole o-phenylenediamine in an organic solvent which has a solubility in water of not more than 5 g/l and has a boiling point above 100° C, at a temperature between 100° and 200° C.